Newspaper Publication - Financial Results

Revenue DeclineCompliance View source PDF

SUVEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+1.3%1-day move

₹209.00

prior close

₹207.62

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.1+0.2+0.1+0.3+1.3+21.2+30.1+28.7+28.7+29.7+12.9+29.3+67.0—

Up moveDown movePending

AI summary

Suven Life Sciences has published its audited financial results for the quarter and year ended March 31, 2026. The company reported total standalone income of ₹152.01 lakhs for Q4 FY26, a slight increase from ₹146.70 lakhs in Q4 FY25. However, the company continues to incur significant losses, with standalone net loss after tax of ₹1,116.73 lakhs for Q4 and ₹5,486.28 lakhs for the full year FY26. On a consolidated basis, the losses are much larger at ₹4,559.55 lakhs for Q4 and ₹27,634.41 lakhs for FY26. Basic EPS stood at ₹(0.50) for Q4 and ₹(2.41) for FY26 standalone, while consolidated EPS was ₹(12.13) for the year. The results appeared in Business Standard and Andhra Prabha newspapers on May 14, 2026.

Likely market impact

The company is reporting deep losses for both standalone and consolidated results, with consolidated losses significantly higher than standalone, indicating potential issues at subsidiary level. The negative EPS and substantial losses suggest financial distress for shareholders.